Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Similar documents
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

The Role of Liver Societies in the Global Viral Hepatitis Response

Glen A Lutchman, MD. Clinical Associate Professor, Medicine - Gastroenterology & Hepatology. Bio

JENNIFER L. BARNES, B.S.

The Role of Liver Societies in the Global Viral Hepatitis Response

Curriculum Vitae. PERSONAL DATA Name: Harriet W. Hopf Birth Place: Madison, WI Citizenship: United States

Viral hepatitis and Hepatocellular Carcinoma

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Harvoni: solution to HCV

Update on Real-World Experience With HARVONI

Update on Hepatitis B and Hepatitis C

Hepatitis Free San Diego Community Health Screenings. Binh N. Tran, PharmD, MS, MBA April 15, 2013

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis C Update: What s New in 2017

Seyed Moayed Alavian Professor of Gastroenterology and Hepatology Editor in-chief of Hepatitis Monthly E mail:

HEPATITIS C TREATMENT UPDATE

2017 UnitedHealthcare Services, Inc.

RE: K23 Mentored Patient-Oriented Research Career Development Award for Hubert Chen

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

CURRICULUM VITAE. Associate Clinical Professor of Medicine, UCSF Medical Director, Acute Care for Elders Unit, San Francisco General Hospital

The Dawn of a New Era: Hepatitis C

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD

New Treatments for HCV: Perspective From Asia

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Hepatocellular carcinoma

29th Viral Hepatitis Prevention Board Meeting

K Award Career Development Plan

Surveillance for Hepatocellular Carcinoma

CURRICULUM VITAE. Miguel Goicoechea, M.D.

Prof. Dr. Sehnaz Karadeniz

Update on Real-World Experience With HARVONI

Treatment of HCC in real life-chinese perspective

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The following page contains the final YODA Project review approving this proposal.

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Dr. Siddharth Srivastava

CSAAH is a National Institute of Health

Don t interfere My first choice is always nucs!

STEVEN S. CHAN. IBM Business Consulting Services, Los Angeles, CA ( ) Senior Management Consultant, Corporate Strategy & Change Group

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

AASLD, Boston, USA, 10 th November 2014 [oral presentation]

Clinical Criteria for Hepatitis C (HCV) Therapy

Hepatitis C Testing and Linkage to Care

Screening for HCCwho,

Does Viral Cure Prevent HCC Development

Tenth Annual UCLA Liver Diseases Symposium

Appendix B Biographical Sketch example

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

PROGRAMME AT A GLANCE

2016 ADHD Conference Speaker Biographies

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Treatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1

CURRICULUM VITAE BRIDGETTE DO, MPH NOVEMBER 2018

2017 UnitedHealthcare Services, Inc.

Date January 20, Contact Information

Uchechukwu Megwalu, MD, MPH

Should Elderly CHC Patients (>70 years old) be Treated?

STOP Hepatocellular Carcinoma

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Management of Chronic Hepatitis B in Asian Americans

Disclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.

Neuroscience, University of Notre Dame. Postdoctoral Scholar Advisors: Dr. Bradley S. Gibson, Dr. Nathan Rose

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Ninth Annual UCLA Liver Diseases Symposium

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

RMIT Chinese Medicine International Collaboration in Research and Education

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Hepatitis C Emerging Treatment Paradigms

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy

See Important Reminder at the end of this policy for important regulatory and legal information.

Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

EDUCATION: 2009 M.A., Azusa Pacific University, Azusa, California (APA Accredited) Master of Arts in Clinical Psychology

Diversity Clinical Research Workshop Invited Faculty

Full Duration Management of Hepatitis C in General Hospital via IT System ---- a case from Peking University People s Hospital

HEPATITIS B MANAGEMENT

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Eric D. Leshikar, Ph.D.

Autoimmune Hepatitis Events Easl

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

MINJI KIM, Ph.D. 530 Parnassus Avenue, Suite 366, San Francisco, CA

Ledipasvir-Sofosbuvir (Harvoni)

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia

AASLD 2017 Viral Hepatitis Debrief

AASLD 2017 Viral Hepatitis Debrief

Transcription:

CLINICAL OFFICES Digestive Health Liver Clinic 900 Blake Wilbur Dr MC 5355 Palo Alto, CA 94304 Tel (650) 498-7999 Fax (650) 724-9454 Liver Transplant Clinic 300 Pasteur Dr A160 Bio MC 5309 Stanford, CA 94305 Tel (650) 498-7878 Fax (650) 498-7888 BIO Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center Medicine - Gastroenterology & Hepatology Dr. Nguyen is Professor of Medicine and Director for the Hepatology Fellowship in the Division of Gastroenterology and Hepatology and Liver Transplant Program at Stanford University Medical Center and Director for the Hepatology Clerkship for Stanford University School of Medicine. She is also a member of the Stanford Cancer Institute, Stanford Bio-X and Stanford Population Science. She has a large and comprehensive practice of general liver as well as liver transplant patients at Stanford University Medical Center and weekly outreach clinics in the San Jose and monthly clinics in San Francisco area. Her research areas include epidemiology, clinical outcomes, translational studies, and therapeutic clinical trials for chronic hepatitis B, chronic hepatitis C, liver cancer/tumors, other chronic liver diseases as cause of liver cancer such as nonalcoholic fatty liver disease and liver transplant-related issues. She has mentored over 130 trainees of diverse backgrounds and levels of training. Her research lab includes trainees who are high school students, undergraduate students, medical students, graduate students in the Masters' in Epidemiology Program or Public Health, interns/residents, gastroenterology/ hepatology fellows, junior faculty, and international visiting scholars. She also serves as Pre-Major Academic Advisor for the undergraduate school. Her research base includes single-center Stanford-based cohorts, multi-center Bay Area consortium, multi-center US consortia as well as collaborative international cohorts. Page 1 of 5

She is active in community outreach efforts locally and nationally including service as executive board of director for nonprofit organizations. She serves in the Education and Hepatology Associate Committees for the American Association for the Study of Liver Diseases (AASLD), and as member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group at AASLD. As Faculty Fellow at the Center for Innovation in Global Health at Stanford University, Dr. Nguyen is active in Global Health with research collaboration and medical education program and exchanges, and ongoing work in and with several countries in the Asia Pacific region. She is a Fellow of the American Association for the Study of Liver Diseases and American Gastroenterological Association Fellow, She is also a member of the European Association for the Study of Liver Diseases, the Asia Pacific Association for the Study of Liver Diseases, and the International Liver Cancer Association. She has served in the Editorial Board for several journals including Gastroenterology, Hepatology, Alimentary Pharmacotherapy and Therapeutics, Journal of Clinical Gastroenterology and Digestive Diseases and Science and as ad hoc reviewer for over 30 scientific journals. CLINICAL FOCUS Hepatology and Liver Transplantation Liver cancer and tumors Chronic hepatitis B and C Non-alcoholic fatty liver disease Cirrhosis 5 OF 10 ACADEMIC APPOINTMENTS Professor - Med Center Line, Medicine - Gastroenterology & Hepatology Member, Bio-X Member, Child Health Research Institute Member, Stanford Cancer Institute ADMINISTRATIVE APPOINTMENTS Chair, Global Outreach Subcommittee, Hepatitis B Special Interest Group, American Association for the Study of Liver Disease (AASLD), (2018- present) International Advisory Board, Lancet Gastroenterology and Hepatology, (2018- present) Professoriate Appointments and Promotions Committee (DoM A&P Committee), Department of Medicine, Stanford University, (2018- present) International Editorial Board, Alimentary Pharmacology and Therapeutics, (2018-2020) Editorial Board, Hepatology, (2017-2019) 5 OF 22 HONORS AND AWARDS Senior Fellow at the Center for Innovation in Global Health, Center for Innovation in Global Helath, Stanford University, Stanford, CA (2015 Oct) Stanford Asian American Faculty Awards, The Asian American Activities Center, Stanford University, Stanford, CA (2015 May) 2015 Divisional Teaching Award, Department of Medicine, Stanford University Medical Center, Palo Alto, CA (2015 Dec) Pacific Free Clinic Physician Service Award, Cardinal Free Clinics, Stanford University School of Medicine (2013 April) The Franklin Edbaugh Advising Award for Faculty, Stanford University School of Medicine (2013 May) 5 OF 11 Page 2 of 5

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS See Administrative Appointment Section above, See above (2013 - present) PROFESSIONAL EDUCATION Fellowship: Stanford University School of Medicine Registrar (2002) CA Medical Education: University of California San Diego School of Medicine (1992) CA B.S., University of California, Irvine, Biological Sciences (1988) M.D., Univ. of California, San Diego, Medicine (1992) M.A.S., Univ. of Calif., San Francisco, Masters of Advanced Studies in Clinical Research (2004) 5 OF 8 COMMUNITY AND INTERNATIONAL WORK Health Needs Assessment and Liver Symposium, Yangon Viral Hepatitis and Liver Cancer 2015: Mongolia National Training Workshop Linkage to care, epidmiology of hepatitis B, hepatitis C, and/or liver cancer in Asia Pacific region Pacific Free Clinic Outreach Liver Clinics, San Jose and San Francisco, San Jose, 231 O'Connor Drive and 200 Jose Figueres Avenue; San Francisco and Daly city Community education, outreach service, and research, San Jose 5 OF 9 LINKS Nguyen Lab: http://med.stanford.edu/nguyenlab.html Research & Scholarship CURRENT RESEARCH AND SCHOLARLY INTERESTS 1. Epidemiology and treatment outcomes of liver cancer focusing on screening, early diagnosis with novel markers, etiologies (viral and nonviral including NALFD), linkage to care, ethnic disparities. 2. Epidemiology and treatment outcomes of chronic hepatitis B and C focusing on linkage to care, real-world cohorts, effects of antiviral therapy on long-term outcomes, understudied populations, and HCV genotypes 4-6. 3. Therapeutic clinical trials phase 2 to 4 for chronic hepatitis B and C and non-alcoholic fatty liver disease and hepatic fibrosis. 4. Health disparities and ethnicity-related issues in risk factors, disease presentation, care delivery/quality/outcomes in liver disease 5. Global health: medical education, public health, and research. Areas with current/recent work/collaboration: China, Taiwan, Hong Kong, South Korea, Mongolia, Myanmar, and Japan. Research methodologies and types of studies: -Cross-sectional, case controlled, and cohort studies with matching methodologies including propensity score matching. -Investigator-initiated clinical cohorts in viral hepatitis and liver cancer: regional and international consortium. -Multicenter therapeutic clinical trials: company sponsored and investigator initiated. -Multicenter federally or foundation funded research consortium -Systematic review and meta-analysis. -National public and private registries such as SEER, NHANES, Truven and Optum. Page 3 of 5

-Translational research in collaboration with virology and immunology laboratories. For more information, please contact my lab at 650-498-6084. CLINICAL TRIALS A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response, Recruiting Gilead Sustained Virologic Response (SVR) Registry, Recruiting Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy, Recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV, Recruiting Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005), Recruiting Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B, Recruiting 5 OF 22 Teaching STANFORD ADVISEES Postdoctoral Faculty Sponsor Yee Hui Yeo Postdoctoral Research Mentor Yee Hui Yeo GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS Epidemiology (Masters Program) Gastroenterology & Hepatology (Fellowship Program) Publications PUBLICATIONS Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Alimentary pharmacology & therapeutics Ji, F., Wei, B., Yeo, Y. H., Ogawa, E., Zou, B., Stave, C. D., Li, Z., Dang, S., Furusyo, N., Cheung, R. C., Nguyen, M. H. 2018 Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet. Gastroenterology & hepatology 2018; 3 (6): 383 403 Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States PLOS ONE Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., Nguyen, M. H. 2017; 12 (3) Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. The American journal of gastroenterology Nguyen, M. H., Trinh, H., Do, S., Nguyen, T., Nguyen, P., Henry, L. 2017 More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver Jun, T. W., Yeh, M. L., Yang, J. D., Chen, V. L., Nguyen, P., Giama, N. H., Huang, C. F., Hsing, A. W., Dai, C. Y., Huang, J. F., Chuang, W. L., Roberts, L. R., Yu, et al Page 4 of 5

2017 5 OF 212 Page 5 of 5